CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chengda Pharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chengda Pharmaceuticals Co Ltd
No. 36
Huanghe Road, Huimin Community, Jiashan
Phone: +86 57384468033p:+86 57384468033 JIAXING, ZHJ  314100  China Ticker: 301201301201
Business Summary
Chengda Pharmaceuticals Co Ltd is a China-based company primarily engaged in pharmaceutical manufacturing. The Company provides contract development and manufacturing organization (CDMO) services for key pharmaceutical intermediates and active pharmaceutical ingredients, and the research, development, production, and sales of L-carnitine series products and active pharmaceutical ingredients, as well as the research and development of stem cell drugs. The Company’s CDMO business mainly provides clients with services such as process development, registration document preparation and submission, stability studies, and custom manufacturing for key pharmaceutical intermediates and active pharmaceutical ingredients. L-carnitine series products include L-carnitine and L-carnitine hydrochloride. The active pharmaceutical ingredients business covers multiple indications, including central nervous system drugs, cardiovascular drugs, and diabetes drugs.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board JianliGe 72 5/9/2020 5/9/2020
Chief Financial Officer ChaoFei 46 5/9/2020 5/9/2020
General Manager, Director GangLu 50 5/9/2020 5/9/2020
11 additional Officers and Directors records available in full report.

General Information
Number of Employees: 659 (As of 12/31/2025)
Outstanding Shares: 154,713,824 (As of 3/31/2026)
Shareholders: 12,962
Stock Exchange: SHE
Fax Number: +86 57384185902


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026